Peptides for TDP-43 Pathology: Targeting ALS and FTLD Aggregates

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

Peptide-based PROTACs offer a revolutionary approach to degrading pathological TDP-43 aggregates, a central feature in ALS and FTLD. This targeted degradation holds immense potential for slowing or halting the progression of these devastating neurodegenerative diseases.

TAR DNA-binding protein 43 (TDP-43) pathology is a central feature in a spectrum of neurodegenerative diseases, most notably amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). In these conditions, TDP-43 misfolds, aggregates, and accumulates in the cytoplasm of neurons and glial cells, leading to cellular dysfunction and death. This pathological aggregation of TDP-43 is considered a major driver of disease progression. While conventional therapeutic approaches have struggled to address this proteinopathy, emerging research suggests that specific peptides, particularly those engineered as proteolysis-targeting chimeras (PROTACs), hold significant promise in degrading pathological TDP-43.

Understanding TDP-43 Proteinopathy

TDP-43 is a nuclear protein involved in various aspects of RNA metabolism, including transcription, splicing, and mRNA transport. Under normal conditions, it is predominantly found in the nucleus. However, in ALS and FTLD, TDP-43 translocates from the nucleus to the cytoplasm, where it forms insoluble aggregates and oligomers. These cytoplasmic inclusions are neurotoxic, impairing cellular processes and leading to neuronal degeneration. The C-terminal fragment of TDP-43 (C-TDP-43) is particularly prone to aggregation and is considered a key pathological agent [Tseng et al., 2023].

Peptide-Based Strategies for TDP-43 Degradation

Targeting misfolded protein aggregates has historically been challenging with conventional drugs. However, peptide-based strategies, especially those leveraging targeted protein degradation, offer a novel approach:

1. Proteolysis-Targeting Chimeras (PROTACs)

PROTACs are heterobifunctional molecules that utilize the cell's ubiquitin-proteasome system (UPS) to selectively degrade target proteins. A PROTAC typically consists of three components: a ligand that binds to the target protein, a ligand that binds to an E3 ubiquitin ligase, and a linker connecting the two. By bringing the target protein (e.g., TDP-43) into close proximity with an E3 ligase, the PROTAC facilitates the ubiquitination of the target, marking it for degradation by the proteasome. This catalytic mechanism allows PROTACs to achieve potent and sustained degradation of target proteins, even at substoichiometric concentrations.

Recent studies have demonstrated the efficacy of PROTACs in degrading pathological TDP-43. For example, Tseng et al. (2023) designed a dual-targeting PROTAC (PROTAC 2) that effectively decreased C-TDP-43 aggregates and oligomers in cellular models, reducing their neurotoxicity without affecting endogenous TDP-43. This PROTAC was shown to bind to C-TDP-43 aggregates and an E3 ligase, initiating ubiquitination and proteolytic degradation. Furthermore, it improved the motility of transgenic C. elegans by reducing C-TDP-43 aggregates in the nervous system. This represents a significant breakthrough in targeting TDP-43 pathology.

2. Aggregation Inhibitors and Disaggregators

While PROTACs promote degradation, other peptide-based strategies focus on preventing TDP-43 aggregation or disassembling pre-formed aggregates. Peptides designed to bind to specific regions of TDP-43 could stabilize its native conformation, preventing misfolding, or interfere with the protein-protein interactions necessary for aggregation. Similarly, peptides capable of disassembling existing aggregates could reduce the burden of toxic inclusions in affected cells.

Challenges and Future Outlook

Despite the promising results with PROTACs and other peptide-based approaches, several challenges remain for clinical translation. These include optimizing brain penetrance, ensuring the specificity of degradation to pathological TDP-43 while sparing physiological TDP-43, and minimizing potential off-target effects. Further research is needed to refine peptide design, develop efficient delivery systems, and conduct comprehensive preclinical and clinical studies to validate their safety and efficacy in human patients. However, the targeted degradation approach offered by PROTACs represents a paradigm shift in treating TDP-43 proteinopathies.

Practical Takeaway

TDP-43 pathology is a critical driver of ALS and FTLD, characterized by the aggregation of misfolded TDP-43 protein. Peptide-based strategies, particularly PROTACs, offer a revolutionary approach to degrading these pathological aggregates by harnessing the cell's natural waste disposal systems. As practitioners, you'll recognize that this targeted degradation represents a significant advancement in addressing previously

undruggable targets. While challenges remain in clinical translation, the potential for peptide-based PROTACs to slow or halt the progression of these devastating neurodegenerative diseases is immense, offering new hope for patients and their families.